茴三硫%干眼病%受体,毒蕈碱%治疗结果
茴三硫%榦眼病%受體,毒蕈堿%治療結果
회삼류%간안병%수체,독심감%치료결과
Anethole trithione%Xerophthalmia%Receptors,muscarinic%Treatment outcome
目的 探讨口服环戊硫酮对干眼的治疗效果.方法 采用前瞻性随机双盲对照研究方法,将2006年12月至2008年8月在厦门大学附属厦门眼科中心眼表疾病专科门诊确诊为干眼的80例患者(80只眼)随机分为两组:口服环戊硫酮组40例、口服维生素C安慰剂对照组40例,各组依评定标准再分为轻度干眼和中重度干眼两个亚组.两组均加用0.05%羧甲基纤维素钠眼液滴眼治疗;分别在治疗前和治疗后3、7、28 d各时间点检测并评定患者干眼主观症状、视力、角膜荧光素染色(F1)、泪膜破裂时间(BUT)及基础泪液分泌试验(SⅠT),治疗前后及两组的各亚组之间均进行重复测量多因素方差分析和样本均数或中位数差值分析.结果 除流泪和眼红外,治疗7 d后,两组的轻度干眼亚组其他干眼症状、F1染色、BUT及SⅠT值均较治疗前有所改善.治疗7 d后,除流泪和眼红外,仅环戊硫酮组中重度干眼亚组的样本均数差值[0.96(视疲劳)、1.26(干涩感)、0.82(异物感)、1.28(烧灼感)、1.05(畏光)、1.48(疼痛)],以及样本中位数差值[0.30(视力)、4.00(F1染色)、5.00(BUT)、5.00(SⅠT)],均较治疗前明显改善[F=15.30(视疲劳),15.68(干涩感),13.56(异物感),20.91(烧灼感),18.90(畏光),27.22(疼痛),10.54(视力),188.21(F1染色),261.76(BUT),269.05(SⅠT);均P<0.05].在全部28 d观察期间内,安慰剂组中重度干眼亚组的样本均数差值[0.10(视疲劳)、0.16(干涩感)、0.09(异物感)、0.38(烧灼感)、0.24(畏光)、0.36(疼痛)、0.23(眼红)],以及样本中位数差值[0.10(视力)、0.50(F1染色)、0.50(BUT)、0.50(SⅠT)],均较治疗前无明显改善[F=1.76(视疲劳),1.61(于涩感),1.02(异物感),2.39(烧灼感),2.42(畏光),2.73(疼痛),2.55(眼红),1.46(视力),2.35(F1染色),2.90(BUT),2.76(SⅠT);均P>0.05].环戊硫酮组SⅠT值较安慰剂组改善更为明显(F=13.77,P<0.05),SⅠT值达正常范围.结论 环戊硫酮可显著改善泪腺功能尚存的中重度十眼的症状和体征,具有临床应用价值.
目的 探討口服環戊硫酮對榦眼的治療效果.方法 採用前瞻性隨機雙盲對照研究方法,將2006年12月至2008年8月在廈門大學附屬廈門眼科中心眼錶疾病專科門診確診為榦眼的80例患者(80隻眼)隨機分為兩組:口服環戊硫酮組40例、口服維生素C安慰劑對照組40例,各組依評定標準再分為輕度榦眼和中重度榦眼兩箇亞組.兩組均加用0.05%羧甲基纖維素鈉眼液滴眼治療;分彆在治療前和治療後3、7、28 d各時間點檢測併評定患者榦眼主觀癥狀、視力、角膜熒光素染色(F1)、淚膜破裂時間(BUT)及基礎淚液分泌試驗(SⅠT),治療前後及兩組的各亞組之間均進行重複測量多因素方差分析和樣本均數或中位數差值分析.結果 除流淚和眼紅外,治療7 d後,兩組的輕度榦眼亞組其他榦眼癥狀、F1染色、BUT及SⅠT值均較治療前有所改善.治療7 d後,除流淚和眼紅外,僅環戊硫酮組中重度榦眼亞組的樣本均數差值[0.96(視疲勞)、1.26(榦澀感)、0.82(異物感)、1.28(燒灼感)、1.05(畏光)、1.48(疼痛)],以及樣本中位數差值[0.30(視力)、4.00(F1染色)、5.00(BUT)、5.00(SⅠT)],均較治療前明顯改善[F=15.30(視疲勞),15.68(榦澀感),13.56(異物感),20.91(燒灼感),18.90(畏光),27.22(疼痛),10.54(視力),188.21(F1染色),261.76(BUT),269.05(SⅠT);均P<0.05].在全部28 d觀察期間內,安慰劑組中重度榦眼亞組的樣本均數差值[0.10(視疲勞)、0.16(榦澀感)、0.09(異物感)、0.38(燒灼感)、0.24(畏光)、0.36(疼痛)、0.23(眼紅)],以及樣本中位數差值[0.10(視力)、0.50(F1染色)、0.50(BUT)、0.50(SⅠT)],均較治療前無明顯改善[F=1.76(視疲勞),1.61(于澀感),1.02(異物感),2.39(燒灼感),2.42(畏光),2.73(疼痛),2.55(眼紅),1.46(視力),2.35(F1染色),2.90(BUT),2.76(SⅠT);均P>0.05].環戊硫酮組SⅠT值較安慰劑組改善更為明顯(F=13.77,P<0.05),SⅠT值達正常範圍.結論 環戊硫酮可顯著改善淚腺功能尚存的中重度十眼的癥狀和體徵,具有臨床應用價值.
목적 탐토구복배무류동대간안적치료효과.방법 채용전첨성수궤쌍맹대조연구방법,장2006년12월지2008년8월재하문대학부속하문안과중심안표질병전과문진학진위간안적80례환자(80지안)수궤분위량조:구복배무류동조40례、구복유생소C안위제대조조40례,각조의평정표준재분위경도간안화중중도간안량개아조.량조균가용0.05%최갑기섬유소납안액적안치료;분별재치료전화치료후3、7、28 d각시간점검측병평정환자간안주관증상、시력、각막형광소염색(F1)、루막파렬시간(BUT)급기출루액분비시험(SⅠT),치료전후급량조적각아조지간균진행중복측량다인소방차분석화양본균수혹중위수차치분석.결과 제류루화안홍외,치료7 d후,량조적경도간안아조기타간안증상、F1염색、BUT급SⅠT치균교치료전유소개선.치료7 d후,제류루화안홍외,부배무류동조중중도간안아조적양본균수차치[0.96(시피로)、1.26(간삽감)、0.82(이물감)、1.28(소작감)、1.05(외광)、1.48(동통)],이급양본중위수차치[0.30(시력)、4.00(F1염색)、5.00(BUT)、5.00(SⅠT)],균교치료전명현개선[F=15.30(시피로),15.68(간삽감),13.56(이물감),20.91(소작감),18.90(외광),27.22(동통),10.54(시력),188.21(F1염색),261.76(BUT),269.05(SⅠT);균P<0.05].재전부28 d관찰기간내,안위제조중중도간안아조적양본균수차치[0.10(시피로)、0.16(간삽감)、0.09(이물감)、0.38(소작감)、0.24(외광)、0.36(동통)、0.23(안홍)],이급양본중위수차치[0.10(시력)、0.50(F1염색)、0.50(BUT)、0.50(SⅠT)],균교치료전무명현개선[F=1.76(시피로),1.61(우삽감),1.02(이물감),2.39(소작감),2.42(외광),2.73(동통),2.55(안홍),1.46(시력),2.35(F1염색),2.90(BUT),2.76(SⅠT);균P>0.05].배무류동조SⅠT치교안위제조개선경위명현(F=13.77,P<0.05),SⅠT치체정상범위.결론 배무류동가현저개선루선공능상존적중중도십안적증상화체정,구유림상응용개치.
Objective To investigate anethol trithione therapic efficiency on dry eye. Methods It was a prospective random double-blind controlled study. Eighty cases diagnosed dry eye in Ocular Surface Out-patient Clinic of Xiamen University Affiliated Xiamen Eye Center from 2006 to 2008 were divided into two groups: anethol trithione group and control group, 40 cases in each group. Every group was then divided into two subgroups: weak dry eye subgroup, middle and severe dry eye subgroup. All groups had been added with 0.05% refresh drops. All patients had been detected and evaluated by subjective symptoms of dry eye, visual acuity,corneal fluorescent staining(F1), break-up time(BUT) and Schirmer Ⅰ test (SⅠT) at pre-therapy and 3,7,28 d of post-therapy. All groups had been compared and analyzed by F test and sample mean difference (SMD) or median difference (MD) comparison between pre-therapy and post-therapy. Results Except of tear and red eye, the other subjective symptoms of dry eye, F1, BUT and SⅠT of weak dry eye subgroup of both groups had been improved at 7 d after therapy. Only those of middle and severe dry eye subgroup of anethol trithione group had been improved at 7 d after therapy compared with those of pre-therapy: SMD=0.96 (visual tiredness), 1.26 (dry and unsmooth sensation), 0.82 (foreign body sensation), 1.28 (burning sensation), 1.05 (photophobia), 1.48 ( pain ) ; MD=0.30 (visual acuity), 4.00 (F1) ,5.00 (BUT), 5.00 (SⅠT) [F=15.30 (visual tiredness), 15.68 (dry and unsmooth sensation ), 13.56 (foreign body sensation), 20. 91 ( burning sensation ), 18.90 (photophobia), 27.22 ( pain ), 10.54 (visual acuity), 188.21 (F1) ,261.76 (BUT) ,269.05 (SⅠT) ;P<0. 05]. Those of middle and severe dry eye subgroup of control group hadn't significantly been improved at 28 d after therapy: SMD=0.10 (visual tiredness) ,0.16 (dry and unsmooth sensation) ,0.09 (foreign body sensation) ,0.38 ( burning sensation ), 0.24(photophobia) ,0.36 (pain) ,0.23 (red eye) ; MD=0.10 (visual acuity) ,0.50(F1) ,0.50(BUT), 0.50(SⅠT) [F=1.76 (visual tiredness), 1.61 (dry and unsmooth sensation), 1.02 (foreign body sensation),2.39 (burning sensation), 2.42 (photophobia), 2.73 ( pain ), 2.55 ( red eye ), 1.46 ( visual acuity) ,2.35 (F1) ,2.90 (BUT) ,2.76 (SⅠT) ; P>0.05]. SⅠT of anethol trithione group had been improved more significantly after therapy (F=13.77, P<0.05). Conclusion Anethol trithione could significantly improve middle and severe dry eye patients' symptoms and signs whose lacrimal gland function survival and it has clinical application value.
